GILD34:BVMF
Gilead Sciences Inc BDR
65,81 BRL
0,00%
(0,00) 1 n
okt. 16., 16:56:00 GMT-3 · BRL
search
Minden szimbólum
| Szimbólum | Ár | Változás | Változás %-ban |
|---|
insights_autoLegfontosabb statisztikák generálása a következőhöz: GILD34…
Megnyitás
66,36 BRL
Magas
66,41 BRL
Alacsony
65,81 BRL
Piaci tőkeérték
193,67 Mrd
Átlagos forgalom
261,00
Forgalom
0,00
52 hetes legmagasabb ár
67,38 BRL
52 hetes legalacsonyabb ár
51,33 BRL
Kinnlevő részvények
1,24 Mrd
Alkalmazottak száma
17 E
Megnyitás
66,36 BRL
Magas
66,41 BRL
Alacsony
65,81 BRL
Piaci tőkeérték
193,67 Mrd
Átlagos forgalom
261,00
Forgalom
0,00
52 hetes legmagasabb ár
67,38 BRL
52 hetes legalacsonyabb ár
51,33 BRL
Kinnlevő részvények
1,24 Mrd
Alkalmazottak száma
17 E
Hírek, történetek
Internetes forrásokból és hírszolgáltató partnerektől
ad-hoc-news.de
·
2 órával ezelőtt
Gilead Sciences stock sits 2.32 percent below its yearly high
ad-hoc-news.de
·
3 órával ezelőtt
Gilead Sciences stock pre-market at EUR 139.78: biotech group slightly higher
The Motley Fool
·
16 órával ezelőtt
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
Simply Wall Street
·
1 nappal ezelőtt
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Gilead Sciences Inc BDR információi
VezérigazgatóDaniel O'Day
Munkavállalók17 E
Alapítva1987. jún. 22.
SzékhelyFoster City, Kalifornia, Egyesült Államok
Ágazat-
Webhelygilead.com